Interventional Cardiology Resource Center Editorial Programs

 
 
  • 'The Providers': A 21st-Century Healthcare Fantasy A physician dreams of an alternate world that eerily mirrors today's healthcare environment.
  • Debating ISAR-REACT 5: Ticagrelor vs Prasugrel in ACS   Which P2Y12 inhibitor to use in patients with ACS? Rob Storey and ISAR investigator Dirk Sibbing debate ticagrelor vs prasugrel after the surprising results of the first head-to-head comparison trial.
  • Are 30-Day Readmission Rules Deadly for Patients? A federal program aimed at lowering hospital readmissions has doctors divided on whether or not it is working -- and if it is actually harming patients.
  • ESC 2019When Guideline Authors Dismiss Important Studies Why does a guideline document on chronic coronary disease exclude the landmark ORBITA trial? Perhaps it's an existential tension, suggests John Mandrola, MD.
  • ESC 2019Mandrola Previews ESC 2019 Read what John Mandrola, MD, is looking forward to in Paris. Despite some advance spoilers, there will be plenty to pique the interest of the average cardiologist.
  • Stop or Switch the Antidiabetic Drug? This woman's hypoglycemia is mild and her diet is poor. Should I change her antidiabetic meds or leave well enough alone?
  • How a Snakebite and Sudden Death Led to Cardiology and Writing   A family history of sudden death was the impetus for author Sandeep Jauhar's fascination with the heart, which led to a career in cardiology and his latest book Heart: A History.
  • 'I Was That Kid': Dr Quinn Capers Inspires #BlackMenInMedicine   Fewer black men are going into medicine today than in 1978. Drs Harrington and Capers discuss how to increase diversity in medicine and why it's important for caregivers to reflect the population they treat.
  • Is Cardiology Overly Enamored of New Unproven Therapies? A review of many cases where study data reversed a common medical practice highlights the need to be slow to embrace unproven therapies and faster to de-adopt ineffective ones, says John Mandrola, MD.
  • A Brief Overview of the Paclitaxel Devices in PAD Controversy   Concerns have been raised about late mortality with paclitaxel-coated balloons and stents in peripheral interventions. The FDA has convened a panel.
  • Paclitaxel in PAD Warnings Echo Past Drug-Eluting Stent Scare A meta-analysis shows a late mortality signal for paclitaxel-coated devices in peripheral interventions, echoing the late stent thrombosis scare tied to first-generation drug-eluting coronary stents.
  • Conveyor Belt Medicine: Where Are the Brakes? Regional systems of care help streamline urgent care but make it difficult to halt false-positive activations in their tracks. Jaya Mallidi, MD, asks for some checkpoints along the way.
  • Life and Times of Leading Cardiologists: Deepak Bhatt   A ruptured appendix and a love for writing helped ignite Bhatt's passion for cardiovascular research and medicine.
  • Calling Time on the Failure in Heart Failure   Optimal medical therapy and recent advances show that heart failure is preventable and not obligatory, Clyde Yancy tells Bob Harrington.
  • ISCHEMIA: Do Baseline Data Hint at Triumph for OMT?   The success of OMT and the decline of patients with severe ischemia may make it difficult for ISCHEMIA to show benefit for revascularization, predicts Mayo Clinic's Raymond Gibbons, MD.
  • Women as One: 'The Sky's the Limit' for Women in Medicine   Roxana Mehran, MD, co-founder of Women as One, explains its mission to coach and mentor female physicians to develop leadership skills, learn negotiation tactics, and maximize their talents.
  • MitraClip for Secondary MR: Patient Selection Will Be Key   Wayne Batchelor, MD, and Catherine Otto, MD, discuss MitraClip for secondary MR. With FDA approval for this indication, how should cardiologists select patients to ensure COAPT-like results ?
  • Hopeful Heart: Hope for Improving QoL in Depressed HF Patients   'Depression kills,' says Bruce Rollman, MD, the lead author of the Hopeful Heart study. Screening can identify HF patients at risk for depression and improve outcomes.
  • ACC 2019What Will a 'Historic Day' for TAVR Mean in Clinical Practice?   Raj Makkar, MD, discusses the PARTNER-3 and Evolut trials of transcatheter aortic valve replacement in low-surgical-risk patients and his registry data on TAVR for bicuspid aortic stenosis at ACC.19.
  • ACC 2019Quick Thoughts on the Wrap-IT Trial An antibiotic-impregnated envelope casing for cardiac implantable devices may lower the risk for infection, but is it enough to justify the costs?